In conjunction with the launch, Watson has 180 days of marketing exclusivity for being the first to file an abbreviated new drug application containing a paragraph IV certification for the 40mg strength.
Watson’s Omeprazole is the generic equivalent to AstraZeneca’s Prilosec delayed-release capsules USP and is indicated for the short-term treatment of active duodenal ulcer.